Tag: 6

NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announces that dosing has commenced at the prestigious Weill Cornell Medicine Multiple Sclerosis Center in New York City, in its ongoing Phase 2 clinical trial evaluating intranasal foralumab in patients with non-active Secondary Progressive Multiple Sclerosis (na-SPMS). This fifth site complements existing sites at Yale University, Johns Hopkins University, Brigham and Women's Hospital, and the University of Massachusetts.

COMMUNIQUE DE PRESSE DU 13 JUIN 2025
RELATIF A LA MISE EN ŒUVRE DU RETRAIT OBLIGATOIRE DE LA SOCIETE

– Rademikibart significantly improved lung function and asthma control in patients with eosinophilic-driven type 2 asthma –

TOKYO, June 13, 2025 (GLOBE NEWSWIRE) -- Lead Real Estate Co., Ltd (Nasdaq: LRE) (“LRE” or “the Company”), a Japanese real estate developer of luxury residential properties including single-family homes and condominiums across Tokyo and Kanagawa prefectures and Sapporo, is announcing the signing of a sales contract for its planned hotel, ENT TERRACE Tsukiji 6 Chome.

WARSAW, Poland, June 13, 2025 (GLOBE NEWSWIRE) -- Pay As You Like campaign promoting modern payments is launched – another edition of We Did It In Poland by WłączeniPlus Foundation. Last year 69% of all retail payments in Poland were cashless transactions. Pay As You Like is intended to show how friendly the cashless payment ecosystem is in Poland, which is used by entrepreneurs and millions of consumers on a daily basis.

SOUTH SAN FRANCISCO, Calif., June 13, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options to purchase an aggregate of 26,000 shares of the Company’s stock (the “Inducement Grant”) to newly hired employees on June 10, 2025 (the “Grant Date”), in connection with the commencement of employment.